All In Biotech

Drug Trial Radar · NCT03747770

Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand

A Community Intervention Effectiveness Study: Single Dose or Two Doses of Bivalent HPV Vaccine (CERVARIX) in Female School Students in Thailand

Last checked: Nov 20, 2026Latest source record: Apr 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

18,000

Planned (sponsor's estimate)

Start

Dec 17, 2018

Primary completion

Dec 2022

Study completion Jun 2023

Sponsor

Lead sponsor
International Vaccine InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, Thailand
First posted
Nov 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 13 years, up to 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a community intervention effectiveness study in female school students in Thailand. The study objectives are: 1. To demonstrate HPV vaccine effectiveness of Single Dose (SD) by a reduction in vaccine-type HPV prevalence (HPV 16 and HPV 18) at Year 2 and Year 4 post vaccination compared to unvaccinated same grade female students 2. To demonstrate that HPV vaccine effectiveness of SD and two-dose (2D) regimens are similar by comparing reductions in vaccine type prevalence at Year 2 and Year 4 post vaccination compared with the baseline surveys in the two provinces

Conditions

  • Healthy

Interventions

  • Bivalent HPV vaccine CERVARIX®Biological

    Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HPV infection prevalenceTime frame: Baseline survey (unvaccinated students) during the first year of the study
  2. HPV infection prevalenceTime frame: Year 2, two years post vaccination
  3. HPV infection prevalenceTime frame: Year 4, four years post vaccination
  4. Identification of HPV circulating strainsTime frame: Baseline survey (unvaccinated students) during the first year of the study
  5. Identification of HPV circulating strainsTime frame: Year 2, two years post vaccination
  6. Identification of HPV circulating strainsTime frame: Year 4, four years post vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ministry of Public Health

    Bangkok, Chang Wat Nonthaburi, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.